Get the Stockscreener App
22.18
12.78%
-3.25
Pre-market:
22.23
0.05
+0.23%
Acadia Pharmaceuticals Inc stock is traded at $22.18, with a volume of 6.64M.
It is down -12.78% in the last 24 hours and down -25.19% over the past month.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
See More
Previous Close:
$25.43
Open:
$24.38
24h Volume:
6.64M
Relative Volume:
3.78
Market Cap:
$3.82B
Revenue:
$1.10B
Net Income/Loss:
$375.65M
P/E Ratio:
10.10
EPS:
2.1963
Net Cash Flow:
$113.59M
1W Performance:
-19.20%
1M Performance:
-25.19%
6M Performance:
+5.82%
1Y Performance:
+4.33%
1-Day Range:
$21.97
$24.38
1-Week Range:
$21.97
$27.48
52-Week Range:
$19.69
$30.96
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Name
Acadia Pharmaceuticals Inc
Sector
Industry
Phone
858-558-2871
Address
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
22.18 | 3.82B | 1.10B | 375.65M | 113.59M | 2.1963 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-26 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Feb-23-26 | Upgrade | Mizuho | Neutral → Outperform |
| Oct-21-25 | Initiated | Citigroup | Buy |
| May-21-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Jan-03-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-07-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Mar-12-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-12-24 | Reiterated | Needham | Buy |
| Jan-30-24 | Initiated | Robert W. Baird | Outperform |
| Jan-24-24 | Upgrade | Needham | Hold → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-14-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-06-23 | Upgrade | Mizuho | Neutral → Buy |
| Oct-17-23 | Initiated | UBS | Buy |
| Oct-10-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-03-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-04-22 | Downgrade | Goldman | Neutral → Sell |
| Nov-01-22 | Initiated | Loop Capital | Hold |
| Aug-08-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-21-22 | Downgrade | Jefferies | Buy → Underperform |
| Jun-16-22 | Upgrade | Jefferies | Hold → Buy |
| Mar-16-22 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-05-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-21-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-01-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Jun-10-21 | Initiated | Berenberg | Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-06-21 | Downgrade | Goldman | Buy → Neutral |
| Apr-06-21 | Downgrade | Jefferies | Buy → Hold |
| Apr-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-05-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-10-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-09-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-09-21 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-09-21 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-09-21 | Downgrade | Stifel | Buy → Hold |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Nov-16-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Initiated | Morgan Stanley | Overweight |
| Jul-07-20 | Upgrade | Stifel | Hold → Buy |
| Apr-16-20 | Initiated | Jefferies | Buy |
| Mar-31-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Dec-16-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Initiated | Oppenheimer | Perform |
| Oct-01-19 | Initiated | RBC Capital Mkts | Outperform |
| Sep-13-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-10-19 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jul-23-19 | Reiterated | Needham | Buy |
| Dec-10-18 | Initiated | Canaccord Genuity | Hold |
| Sep-21-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-09-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Initiated | Stifel | Hold |
| Aug-06-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
View All
Acadia Pharmaceuticals Inc Stock (ACAD) Latest News
ACADIA Pharmaceuticals (ACAD) Gets ‘Sell’ Rating on Weak Trial Results, Shares Fall 13% - finance.yahoo.com
Acadia Pharmaceuticals Fell 19% Today. Here’s Where the Stock Could Go in 2026 - finance.yahoo.com
Acadia Alters Phase III Trials To Help Remlifanserin Succeed In Alzheimer’s Psychosis - insights.citeline.com
ACAD Stock Clocks Worst Day In 2 Years After Alzheimer’s Psychosis Drug Misses Main Goal — Citi Cuts Drug’s Success Odds To 20% - finance.yahoo.com
Acadia reports Phase 3-enabling Phase 2 topline for remlifanserin in AD psychosis; 60 mg shows nominal CGI-S significance - TradingView
Biotech Rattled On Surprise Setback For Alzheimer's Drug - Investor's Business Daily
ACADIA Pharma's price target cut after mixed Al... - Pluang
Goldman Sachs reiterates Acadia Pharmaceuticals stock Sell rating after trial miss - Investing.com Canada
TD Cowen reiterates Acadia Pharmaceuticals stock rating on trial data By Investing.com - Investing.com Canada
ACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease PsychosisSlideshow (NASDAQ:ACAD) 2026-09-24 - Seeking Alpha
Why Is Acadia Pharmaceuticals Stock Tumbling Today?ACADIA Pharmaceuticals (NASDAQ:ACAD) - Benzinga
BMO cuts Acadia Pharmaceuticals stock price target on trial miss - Investing.com
BMO cuts Acadia Pharmaceuticals stock price target on trial miss By Investing.com - Investing.com Canada
Acadia Pharmaceuticals: Remlifanserin Is In Trouble (NASDAQ:ACAD) - Seeking Alpha
ACADIA Pharmaceuticals (ACAD) Reiterated by Needham -- Price Tar - GuruFocus
ACADIA Pharmaceuticals (ACAD) Drops 8.6% to $23.25 - AlphaStreet
Acadia's Alzheimer's psychosis drug remlifanserin posts Phase 3-enabling Phase 2 results - Dealroom
Acadia Pharmaceuticals shares slide on mixed Alzheimer's psychosis data - Yahoo Finance
ACADIA Advances 60 mg Remlifanserin After Near-Miss in Alzheimer’s Psychosis Trial - finance.yahoo.com
Acadia drug fails mid-stage study in Alzheimer’s psychosis, leading to modified Phase 3 - Endpoints News
Acadia slides on Phase 2 miss in Alzheimer’s psychosis but keeps moving asset forward - BioSpace
Why is ACADIA Pharmaceuticals stock tumbling today? By Investing.com - Investing.com Canada
Acadia Pharmaceuticals Shares Fall After RADIANT Phase 2 Study Misses Primary Endpoint - finance.yahoo.com
Acadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuing - Fierce Biotech
Sector Update: Healthcare Stocks Mixed Pre-Bell Thursday - finance.yahoo.com
Acadia falls after mid-stage trial setback for Alzheimer’s psychosis therapy - TradingView
Why is ACADIA Pharmaceuticals stock sliding today? By Investing.com - Investing.com Canada
Acadia's Alzheimer's psychosis drug misses main goal of mid-stage study - marketscreener.com
ACADIA Pharmaceuticals' Shares Drop 10% Pre-Bell After Remlifanserin Study Misses Main Endpoint - marketscreener.com
ACAD Looks 0.8% Undervalued on GF Value™ as Clinical Trial Progr - GuruFocus
Acadia reports phase 2 results for Alzheimer’s psychosis drug - Investing.com
Acadia Pharmaceuticals stock tumbles on mixed trial results By Investing.com - Investing.com Nigeria
Acadia Pharmaceuticals stock tumbles on mixed trial results - Investing.com
A second measure favored the higher dose. The Alzheimer’s drug narrowly missed its main test. - stocktitan.net
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP) - STT Info
ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts - Yahoo Finance Singapore
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - ca.finance.yahoo.com
Acadia Pharmaceuticals Announces Phase 3 Enabli… - uniindia.com
ACAD Stock Eyes Best Day In Over A Year As CHMP Recommends Approval For Rare Nerve Disorder Drug In Europe - Stocktwits
Acadia Pharma (ACAD): Will Remlifanserin Data Unlock A New Growth Opportunity? - RTTNews
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
Form 8K ACADIA Pharmaceuticals Inc For: 11 September By Investing.com - Investing.com Nigeria
Acadia Pharmaceuticals announces preliminary court approval of settlement in stockholder derivative action - Investing.com
Acadia Pharmaceuticals Announces Preliminary Court Approval of Stockholder Derivative Lawsuit Settlement - Kalkine Media
ACADIA PHARMACEUTICALS INC Reports Material Event - Stock Titan
Avoiding Lag: Real-Time Signals in (ACAD) Movement - Stock Traders Daily
Acadia Pharma GLP-1 Receptor Agonists Weight Management Diabetes Treatments *zLHGd49l0* - akhmetovfoundation.org
Canaccord Genuity Reaffirms Their Buy Rating on ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Canaccord reiterates Acadia Pharmaceuticals stock rating on products By Investing.com - Investing.com India
Why Is Acadia (ACAD) Up 0.5% Since Last Earnings Report? - finance.yahoo.com
ACADIA Pharmaceuticals (NASDAQ:ACAD) Gains As Fundamentals Improve - Kalkine Media
Acadia Pharmaceuticals Inc Stock (ACAD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):